Receive $200 for creating an Interactive Brokers account using our link: Create IBKR account. Read our Interactive Brokers analysis

Ticker
HAE

Price
58.59
Stock movement up
+0.83 (1.44%)
Company name
Haemonetics Corporation
Exchange
(NYSE
,
Currency
USD
)
Sector
Healthcare >
Medical Devices
Market cap
2.72B
Ent value
3.94B
Price/Sales
2.07
Price/Book
2.99
Div yield
-
Div growth
-
Growth years
-
FCF payout
-
Trailing P/E
15.52
Forward P/E
11.01
PEG
-
EPS growth
17.48%
1 year return (CAGR)
-5.94%
3 year return (CAGR)
-10.01%
5 year return (CAGR)
-15.67%
10 year return (CAGR)
6.08%
Last updated: 2026-02-24

DIVIDENDS

HAE does not pay dividends or no data was received

iO Charts is a Seeking Alpha partner

VALUATION

Valuation Ratios

Loading...
Valuation Ratios data
Trailing P/E15.52
Price to OCF8.04
Price to FCF8.84
Price to EBITDA7.25
EV to EBITDA10.49

Valuation (Sales/Book Value)

Loading...
Valuation (Sales/Book Value) data
Price to Sales2.07
Price to Book2.99
EV to Sales2.99

iO Charts is a Seeking Alpha partner

FINANCIALS

Per share

Loading...
Per share data
Current share count46.47M
EPS (TTM)3.73
FCF per share (TTM)6.56

Income statement

Loading...
Income statement data
Revenue (TTM)1.32B
Gross profit (TTM)771.06M
Operating income (TTM)253.26M
Net income (TTM)175.44M
EPS (TTM)3.73
EPS (1y forward)5.32

Margins

Loading...
Margins data
Gross margin (TTM)58.49%
Operating margin (TTM)19.21%
Profit margin (TTM)13.31%

Balance Sheet

Loading...
Please create a free account or log in to access this chart
Balance Sheet data
Cash363.37M
Net receivables195.71M
Total current assets943.67M
Goodwill606.83M
Intangible assets419.73M
Property, plant and equipment836.81M
Total assets2.49B
Accounts payable48.69M
Short/Current long term debt1.22B
Total current liabilities539.87M
Total liabilities1.58B
Shareholder's equity911.45M
Net tangible assets0.00

Cash flow

Loading...
Please create a free account or log in to access this chart
Cash flow data
Operating cash flow (TTM)338.84M
Capital expenditures (TTM)30.76M
Free cash flow (TTM)308.07M
Dividends paid (TTM)0.00

Financial returns

Loading...
Please create a free account or log in to access this chart
Financial returns data
Return on Equity19.25%
Return on Assets7.04%
Return on Invested Capital8.21%
Cash Return on Invested Capital14.42%

iO Charts is a Seeking Alpha partner

iO Charts is a Seeking Alpha partner

STOCK INFORMATION

Stock chart

Loading...
Stock price data
Open58.90
Daily high59.47
Daily low58.00
Daily Volume737K
All-time high139.48
1y analyst estimate88.00
Beta0.27
EPS (TTM)3.73
Dividend per share0.00
Ex-div date-
Next earnings date7 May 2026

Downside potential

Loading...
Downside potential data
HAES&P500
Current price drop from All-time high-57.99%-1.82%
Highest price drop-68.62%-56.47%
Date of highest drop27 Jan 20229 Mar 2009
Avg drop from high-23.57%-10.84%
Avg time to new high35 days12 days
Max time to new high1527 days1805 days

iO Charts is a Seeking Alpha partner

iO Charts is a Seeking Alpha partner

COMPANY DETAILS
HAE (Haemonetics Corporation) company logo
Marketcap
2.72B
Marketcap category
Mid-cap
Description
Haemonetics Corporation, a medical technology company, provides a suite of hospital technologies solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions, including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 tools. It also provides treatment in electrophysiology, critical care, neurocritical care, trauma, burn surgery, spine surgery, and cancer surgery; SavvyWire, a sensor-guided 3-in-1 guidewire for TAVR procedures; and OptoWire, a pressure guidewire that measures fractional flow reserve and diastolic pressure ratio, as well as fiber optic sensor solutions used in medical devices and other critical industrial applications. In addition, the company offers hospital products comprising TEG and HAS hemostasis analyzer systems that provide a comprehensive assessment of a patient's overall hemostasis; and TEG Manager software, which connects various TEG analyzers throughout the hospital, providing clinicians remote access to active and historical test results that inform treatment decisions. Further, it provides Cell Saver Elite +, an autologous blood recovery system for cardiovascular, orthopedic, trauma, transplant, vascular, obstetrical, and gynecological surgeries; and VASCADE closure products comprising VASCADE 5F, VASCADE 6/7F, VASCADE MVP XL, and VASCADE MVP, a technology platform which offers catheter-based delivery system and leverages the natural clot-inducing properties of collagen. The company sells its products through direct sales force, independent distributors, clinical specialists, and sales representatives. Haemonetics Corporation was founded in 1971 and is headquartered in Boston, Massachusetts.
Employees
3023
Investor relations
-
SEC filings
CEO
Christopher A. Simon
Country
USA
City
Boston
Stock type
Common stock
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
UNDERSTAND THE BUSINESS
Loading...